METTL9 as a protein biomarker predicts the prognosis and immunotherapy response of skin-cutaneous melanoma

The role of methyltransferase-like proteins (METTLs) in skin cutaneous melanoma (SKCM) remains unclear. This study investigates the expression of METTLs, particularly METTL9, in SKCM and its clinical significance. Through multiple database analyses and immunohistochemical experiments, we found that...

Full description

Saved in:
Bibliographic Details
Published inAnnals of medicine and surgery Vol. 87; no. 8; pp. 4918 - 4925
Main Authors Tang, Song, Zhang, Yiran, Luo, Simin, Wang, Wendan, Wu, Xunxin, Zhao, Xiaoxu, Leng, Yin
Format Journal Article
LanguageEnglish
Published England Lippincott Williams & Wilkins 01.08.2025
Subjects
Tumour Marker Prognostic Study
prognostic biomarkers
human methyltransferase-like proteins
therapeutic targets
skin cutaneous melanoma
METTL9
Online AccessGet full text

Cover

More Information
Summary:The role of methyltransferase-like proteins (METTLs) in skin cutaneous melanoma (SKCM) remains unclear. This study investigates the expression of METTLs, particularly METTL9, in SKCM and its clinical significance. Through multiple database analyses and immunohistochemical experiments, we found that METTL9 is significantly upregulated in SKCM tissues, and its expression level is closely associated with tumor-node-metastasis stage, N stage, and ulceration status. Patients with high METTL9 expression have a poor prognosis and show a reduced response to immunotherapy. Furthermore, METTL9 is identified as an independent risk factor for poor prognosis in SKCM patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2049-0801
2049-0801
DOI:10.1097/MS9.0000000000003480